Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr-1(-) cells cytotoxic against the tumor cells.
Tumor cell expansion relies on nutrient supply, and oxygen limitation is central in controlling neovascularization and tumor spread. Monocytes infiltrate into tumors from the circulation along defined chemotactic gradients, differentiate into tumor-associated macrophages (TAMs), and then accumulate in the hypoxic areas. Elevated TAM density in some regions or overall TAM numbers are correlated with increased tumor angiogenesis and a reduced host survival in the case of various types of tumors. To evaluate the role of TAMs in tumor growth, we here specifically eliminated TAMs by in vivo application of dichloromethylene diphosphonate (DMDP)-containing liposomes to mice bearing various types of tumors (e.g., B16 melanoma, KLN205 squamous cell carcinoma, and 3LL Lewis lung cancer), all of which grew in the dermis of syngeneic mouse skin. When DMDP-liposomes were injected into four spots to surround the tumor on day 0 or 5 after tumor injection and every third day thereafter, both the induction of TAMs and the tumor growth were suppressed in a dose-dependent and injection number-dependent manner; and unexpectedly, the tumor cells were rejected by 12 injections of three times-diluted DMDP-liposomes. The absence of TAMs in turn induced the invasion of inflammatory cells into or around the tumors; and the major population of effector cells cytotoxic against the target tumor cells were CD11b(+) monocytic macrophages, but not CCR3(+) eosinophils or Gr-1(+) neutrophils. These results indicate that both the absence of TAMs and invasion of CD11b(+) monocytic macrophages resulted in the tumor rejection.
Department of Physiology, Osaka Medical College, Daigaku-machi, Takatsuki, Japan.
Takeshi
T
Takahashi
Minenori
M
Ibata
Zhiqian
Z
Yu
Yosuke
Y
Shikama
Yasuo
Y
Endo
Yasunori
Y
Miyauchi
Masanori
M
Nakamura
Junko
J
Tashiro-Yamaji
Sayako
S
Miura-Takeda
Tetsunosuke
T
Shimizu
Masashi
M
Okada
Koichi
K
Ueda
Takahiro
T
Kubota
Ryotaro
R
Yoshida
D000818:Animals; D039481:CD11b Antigen / Q000096:biosynthesis / Q000276:immunology; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy; D045744:Cell Line, Tumor; D004002:Clodronic Acid / Q000008:administration & dosage* / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D007150:Immunohistochemistry; D007271:Injections, Intradermal; D008081:Liposomes; D008264:Macrophages / Q000187:drug effects / Q000276:immunology*; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology*; D054397:Receptors, CCR3 / Q000096:biosynthesis / Q000276:immunology; D019707:Receptors, Chemokine / Q000096:biosynthesis / Q000276:immunology
D039481:CD11b Antigen; C515351:Ccr3 protein, mouse; C503133:Gr-1 protein, mouse; D008081:Liposomes; D054397:Receptors, CCR3; D019707:Receptors, Chemokine; D004002:Clodronic Acid